Is HBeAg loss a sign of recovery? How far is it from a functional cure?
HBeAg loss is not the same as anti-HBe seroconversion or a functional cure, and HBeAg-negative hepatitis can still be active.
Source-backed
What a borderline anti-HBs value means, why vaccine immunity differs from recovery, and when to repeat the test.
anti-HBs is the antibody against hepatitis B surface antigen. It can come from a completed hepatitis B vaccine series, or from clearing HBsAg after infection and developing protective antibody. Both are called "anti-HBs positive", but they mean different things and lead to different next steps.
Never read anti-HBs alone. Read it with HBsAg and anti-HBc: HBsAg positive means surface antigen is still present; anti-HBc positive usually means current or past infection. Only together can a clinician tell vaccine immunity, recovery from past infection, and changes during chronic infection apart.
Many laboratories use 10 mIU/mL as the reference threshold for protective antibody, so 10.4 sits just above the line. Reagents, units, and cut-offs differ between laboratories, and the closer a value is to the threshold, the more it needs the full report and earlier results to interpret.
If HBsAg is negative, anti-HBc is negative, and you completed the vaccine series, 10.4 can usually be read as a vaccine response. That does not mean other risks can be ignored, and it does not automatically mean you need a booster.
First, after vaccination: completed series, HBsAg negative, anti-HBc negative, anti-HBs above the line. Routine boosters are generally not needed, but health care workers, dialysis patients, people on immune-suppressing treatment, and partners of people with hepatitis B can ask a clinician whether retesting or a booster is appropriate.
Second, after infection: HBsAg was positive, and during follow-up HBsAg falls or clears while anti-HBs appears. That is the direction of functional cure, but it needs confirmation that HBsAg stays negative and HBV DNA is undetectable, and a clinician must judge it. One result is not a reason to stop treatment or declare a cure.
A value sitting at 10 mIU/mL can shift with reagents, lot numbers, blood collection, and storage. The safer approach is to repeat the test at the same laboratory with the same method, together with older results, rather than comparing single numbers across hospitals.
If anti-HBs turns from negative to around 10 while HBsAg is still positive, that antibody does not mean the same thing as vaccine immunity. A clinician needs to interpret it with HBV DNA, ALT, quantitative HBsAg, and current treatment.
Falling quantitative HBsAg, undetectable HBV DNA, and newly appearing anti-HBs is good news, but follow-up must continue: HBsAg, HBV DNA, ALT, and fibrosis assessment should stay on the clinician's schedule so the change is confirmed as sustained.
People taking antivirals should not stop because anti-HBs appeared. Stopping needs an assessment of cirrhosis, HBsAg status, duration of viral suppression, and follow-up capacity, with close monitoring afterwards.
Keep HBsAg, anti-HBs, anti-HBc, HBV DNA, and ALT results in one folder. Confirm borderline anti-HBs values at the same laboratory. Do not stop antivirals because one anti-HBs result crossed the line. Ask whether you need a booster if you are in a high-risk group. Seek care promptly for jaundice, dark urine, marked fatigue, or abdominal swelling.
Serology interpretation
CDC testing guidance explains anti-HBs together with HBsAg and anti-HBc; one antibody value is not enough to judge immunity.
Vaccine response and protective antibody
CDC vaccine guidance uses a protective anti-HBs level as the marker of vaccine response and lists groups who may need retesting or boosters.
Functional cure and HBsAg clearance
WHO 2024 guidance treats HBsAg clearance as the ideal endpoint and emphasizes long-term treatment and follow-up for most people.
Patient education on antibody results
Hepatitis B Foundation patient resources explain that antibody results must be read with vaccine and infection history.
Stopping treatment
AASLD guidance requires cirrhosis status, viral suppression, and follow-up capacity to be assessed before stopping treatment.
HBeAg loss is not the same as anti-HBe seroconversion or a functional cure, and HBeAg-negative hepatitis can still be active.
Why hepatitis D depends on hepatitis B, which HBsAg-positive people should ask about HDV testing, and what to do after a positive or high-risk result.
What to prepare when hepatitis B overlaps with HIV, hepatitis C, or related treatment decisions, and why HBV-active medicines should not be stopped on your own.